Literature DB >> 35788704

Evaluation of pediatric malignancies using total-body PET/CT with half-dose [18F]-FDG.

Wanqi Chen1,2, Lei Liu1,2, Yinghe Li1,2, Shatong Li1,2, Zhijian Li1,2, Weiguang Zhang1,2, Xu Zhang1,2, Runze Wu3, Debin Hu3, Hongyan Sun3, Yun Zhou3, Wei Fan1,2, Yumo Zhao4,5, Yizhuo Zhang6,7, Yingying Hu8,9.   

Abstract

PURPOSE: To explore the impact of a true half dose of [18F]-FDG on image quality in pediatric oncological patients undergoing total-body PET/CT and investigate short acquisition times with half-dose injected activity.
METHODS: One hundred pediatric oncological patients who underwent total-body PET/CT using the uEXPLORER scanner after receiving a true half dose of [18F]-FDG (1.85 MBq/kg) were retrospectively enrolled. The PET images were first reconstructed using complete 600-s data and then split into 300-s, 180-s, 60-s, 40-s, and 20-s duration groups (G600 to G20). The subjective analysis was performed using 5-point Likert scales. Objective quantitative metrics included the maximum standard uptake value (SUVmax), SUVmean, standard deviation (SD), signal-to-noise ratio (SNR), and SNRnorm of the background. The variabilities in lesion SUVmean, SUVmax, and tumor-to-background ratio (TBR) were also calculated.
RESULTS: The overall image quality scores in the G600, G300, G180, and G60 groups were 4.9 ± 0.2, 4.9 ± 0.3, 4.4 ± 0.5, and 3.5 ± 0.5 points, respectively. All the lesions identified in the half-dose images were localized in the G60 images, while 56% of the lesions could be clearly identified in the G20 images. With reduced acquisition time, the SUVmax and SD of the backgrounds were gradually increased, while the TBR values showed no statistically significant differences among the groups (all p > 0.1). Using the half-dose images as a reference, the variability in the lesion SUVmax gradually increased from the G180 to G20 images, while the lesion SUVmean remained stable across all age groups. SNRnorm was highly negatively correlated with age.
CONCLUSION: Total-body PET/CT with a half dose of [18F]-FDG (1.85 MBq/kg, estimated whole-body effective dose: 1.76-2.57 mSv) achieved good performance in pediatric patients, with sufficient image quality and good lesion conspicuity. Sufficient image quality and lesion conspicuity could be maintained at a fast scanning time of 60 s with half-dose activity.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Low dose; Pediatric; Total-body PET/CT; [18F]-FDG

Mesh:

Substances:

Year:  2022        PMID: 35788704     DOI: 10.1007/s00259-022-05893-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  39 in total

Review 1.  Role of Reference Levels in Nuclear Medicine: A Report of the SNMMI Dose Optimization Task Force.

Authors:  Adam M Alessio; Mary Beth Farrell; Frederic H Fahey
Journal:  J Nucl Med       Date:  2015-09-24       Impact factor: 10.057

2.  The new EANM paediatric dosage card: additional notes with respect to F-18.

Authors:  M Lassmann; L Biassoni; M Monsieurs; C Franzius
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-24       Impact factor: 9.236

3.  2016 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities.

Authors:  S Ted Treves; Michael J Gelfand; Frederic H Fahey; Marguerite T Parisi
Journal:  J Nucl Med       Date:  2016-12       Impact factor: 10.057

4.  Minimizing and communicating radiation risk in pediatric nuclear medicine.

Authors:  Frederic H Fahey; S Ted Treves; S James Adelstein
Journal:  J Nucl Med       Date:  2011-07-15       Impact factor: 10.057

5.  Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma.

Authors:  Fabien Ricard; Sébastien Cimarelli; Emmanuel Deshayes; Thomas Mognetti; Philippe Thiesse; Francesco Giammarile
Journal:  Clin Nucl Med       Date:  2011-08       Impact factor: 7.794

Review 6.  Operational and Dosimetric Aspects of Pediatric PET/CT.

Authors:  Frederic H Fahey; Alison Goodkind; Robert D MacDougall; Leah Oberg; Sonja I Ziniel; Richard Cappock; Michael J Callahan; Neha Kwatra; S Ted Treves; Stephan D Voss
Journal:  J Nucl Med       Date:  2017-07-07       Impact factor: 10.057

7.  18F-Flurodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) findings in children with encephalitis and comparison to conventional imaging.

Authors:  Sophie Turpin; Patrick Martineau; Marc-André Levasseur; Inge Meijer; Jean-Claude Décarie; Julie Barsalou; Christian Renaud; Hélène Decaluwe; Elie Haddad; Raymond Lambert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-12       Impact factor: 9.236

8.  Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma.

Authors:  R A J Nievelstein; H M E Quarles van Ufford; T C Kwee; M B Bierings; I Ludwig; F J A Beek; J M H de Klerk; W P Th M Mali; P W de Bruin; J Geleijns
Journal:  Eur Radiol       Date:  2012-04-27       Impact factor: 5.315

9.  Paediatric nuclear medicine practice: an international survey by the IAEA.

Authors:  G L Poli; L Torres; M Coca; M Veselinovic; M Lassmann; H Delis; F Fahey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-08       Impact factor: 9.236

Review 10.  Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review.

Authors:  Soni C Chawla; Noah Federman; Di Zhang; Kristen Nagata; Soujanya Nuthakki; Michael McNitt-Gray; M Ines Boechat
Journal:  Pediatr Radiol       Date:  2009-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.